Health · Pharma & Biotech · 1 hr ago
Biogen awaits results from two late-stage lupus drug studies
Biogen is awaiting results from two Phase 3 studies of its lupus drug litifilimab.
The company expects the results in the first half of December from the twin TOPAZ-1 and TOPAZ-2 studies.
The studies test litifilimab as a treatment for lupus, an autoimmune disease.
More than two years ago, a different Biogen lupus drug, dapirolizumab, produced positive results in a Phase 3 study.
The new results will test Biogen's research and growth strategy, put in place by CEO Chris Viehbacher after he joined in 2022.
The outcome is a risky test for the company, and the results are expected in December.
Biogen is awaiting results from two Phase 3 studies of lupus drug litifilimab.
The TOPAZ-1 and TOPAZ-2 study results are expected in the first half of December.
The results will test the company’s research and development revamp and growth strategy.
Biogen announced positive results from a Phase 3 lupus study of another drug, dapirolizumab, more than two years earlier.
- Who
- Biogen.
- What
- The company is awaiting results from two Phase 3 studies of litifilimab, a lupus drug.
- When
- The results are expected in the first half of December.
- Where
- Not stated.
- Why
- The results will test Biogen’s research and development revamp and growth strategy.
This story does not have two clearly opposing sides.
Biogen announced positive results from a Phase 3 study of lupus drug dapirolizumab.
Results are expected from the TOPAZ-1 and TOPAZ-2 Phase 3 studies of litifilimab.
- Drug
- Litifilimab
- Studies
- TOPAZ-1 and TOPAZ-2
- Stage
- Phase 3
- Expected readout
- First half of December
- Earlier lupus study
- Dapirolizumab Phase 3 results were positive
What people are saying
The drug was dapirolizumab and the outcome was positive, in case you were wondering.